Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

8306	Companies
115328	Keywords
55598	Articles
62613	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 04/08/2024 at 23:01, 7 months 13 days ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 7 months 13 days ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
BRIEF

published on 04/04/2024 at 23:05, 7 months 17 days ago

Biophytis Announces Unanimous Approval in General Meeting

Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE

published on 04/04/2024 at 23:00, 7 months 17 days ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30%

Shareholders Biophytis General Meeting Resolutions Approval
REGULATED PRESS RELEASE

published on 04/04/2024 at 23:00, 7 months 17 days ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces approval of all resolutions at the Combined General Meeting held on April 2, 2024, with significant shareholder turnout. The Company specializes in therapeutics for age-related diseases

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF

published on 03/22/2024 at 07:05, 8 months ago

Biophytis Unveils Phase 3 Sarcopenia Treatment Protocol

Biophytis Clinical Research RuvembriTM Sarcopenia Phase 3 Study
PRESS RELEASE

published on 03/22/2024 at 07:01, 8 months ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presented its phase 3 protocol for treating sarcopenia with Ruvembri at ICFSR conference, showing promising results in phase 2 study

Biophytis Ruvembri Phase 3 Protocol Sarcopenia Treatment ICFSR Conference
REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 8 months ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presents phase 3 protocol for sarcopenia treatment at ICFSR conference, showcasing the potential of RuvembriTM. CEO Stanislas Veillet seeks partners for drug development and financing

Biophytis RuvembriTM Clinical-stage Biotechnology Phase 3 Protocol Sarcopenia Treatment
BRIEF

published on 03/18/2024 at 07:05, 8 months 4 days ago

Biophytis Announces Combined General Meeting for April 2024

Biophytis RuvembriTM Clinical-stage Biotechnology Combined General Meeting Age-related Diseases
REGULATED PRESS RELEASE

published on 03/18/2024 at 07:00, 8 months 4 days ago

Combined General Meeting of April 2, 2024
Biophytis SA will hold its Combined General Meeting (CGM) on April 2, 2024 at Sorbonne Université, Paris. Shareholders can vote in advance. The company specializes in developing therapies for age-related diseases

Therapeutics Combined General Meeting Biophytis SA Age-related Diseases CGM

Accesswire

Published on 11/22/2024 at 16:00, 1 hour 5 minutes ago

Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Published on 11/22/2024 at 15:55, 1 hour 10 minutes ago

Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 1 hour 50 minutes ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 2 hours 20 minutes ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Published on 11/22/2024 at 14:30, 2 hours 35 minutes ago

Allied Universal Named Presenting Sponsor of 2024 Lott IMPACT Trophy Recognizing College Football's Defensive Best

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 16:55, 9 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 hour 5 minutes ago

Proposed cancellation of admission to trading
Published on 11/22/2024 at 16:00, 1 hour 5 minutes ago

AlphaX Makes Crypto Easier with Email Login and USDT Memecoins
Published on 11/22/2024 at 15:27, 1 hour 38 minutes ago

EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
Published on 11/22/2024 at 14:46, 2 hours 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company

Les Echos

Published on 11/22/2024 at 14:35, 2 hours 30 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 1 day 10 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 21 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 23 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 23 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE